glp-1 agonists cardiovascular diseases Frontiers Cardiovascular disease continuum-GLP-1 action. Adapted
Description
Tirzepatide (weekly dual GIP + GLP-1 agonist
performed on 40 randomized clinical trials including T2DM patients showed that GLP1-RAs reduce oxidative stress and the levels of inflammatory markers including CRP [50]
L.ShenH.LiuL.WangL.LiB.FangP.et al
But GLP-1 agonists seemed to act differently: The direct administration of the drugs to AP, but not NST, caused weight loss
doi: 10.1016/j.molmet.2018.09.009 64 BerndtSIGustafssonSMgiRGannaAWheelerEFeitosaMFet al
